Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. by Tam, Oliver H et al.
UC Irvine
UC Irvine Previously Published Works
Title
Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon 
Activation, Oxidative Stress, and Activated Glia.
Permalink
https://escholarship.org/uc/item/5766w3mq
Journal
Cell reports, 29(5)
ISSN
2211-1247
Authors
Tam, Oliver H
Rozhkov, Nikolay V
Shaw, Regina
et al.
Publication Date
2019-10-01
DOI
10.1016/j.celrep.2019.09.066
License
https://creativecommons.org/licenses/by/4.0/ 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Postmortem Cortex Samples Identify Distinct Molecular 
Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, 
and Activated Glia
Oliver H. Tam1,9, Nikolay V. Rozhkov1,9, Regina Shaw1,9, Duyang Kim2, Isabel Hubbard2,10, 
Samantha Fennessey2, Nadia Propp2, The NYGC ALS Consortium, Delphine Fagegaltier2, 
Brent T. Harris3,4, Lyle W. Ostrow3,5, Hemali Phatnani2,3, John Ravits3,6, Josh Dubnau3,7,8, 
Molly Gale Hammell1,3,11,*
1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
2Center for Genomics of Neurodegenerative Disease, New York Genome Center, New York, NY 
10013, USA
3The NYGC ALS Consortium
4Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA
5Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, 
USA
6Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA
7Department of Anesthesiology, Stony Brook University, Stony Brook, NY 11794, USA
8Department of Neurobiology and Behavior, Stony Brook University, Stony Brook, NY 11794, USA
9These authors contributed equally
10Present address: Department of Neurobiology and Behavior, Renaissance School of Medicine, 
Stony Brook University, Stony Brook, NY 11794, USA
11Lead Contact
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
*Correspondence: mhammell@cshl.edu.
AUTHOR CONTRIBUTIONS
O.H.T., M.G.H., and J.D. designed the study. N.V.R. designed and performed the experiments identifying TDP-43 targets in SH-SY5Y 
cells. R.S. designed and performed the experiments on the UCSD ALS patient samples. J.R. provided the UCSD ALS patient samples 
and associated clinical and diagnostic data. In the NYGC ALS Consortium, members contributed ALS patient samples and clinical 
information. D.K. curated de-identified clinical data and C9orf72 genotype information. I.H. and N.P. coordinated study materials and 
processed samples for sequencing. S.F. oversees Consortium resources and data distribution. D.F. and H.P. designed the methodology, 
reviewed sample preparation and data quality, and coordinated the research activity of NYGC ALS Consortium postmortem core 
RNA-seq experiments. B.T.H. supervised the neuropathological analysis of the immunohistochemical staining results. L.W.O. 
coordinated the post-mortem tissue, slide, and data collection through the Target ALS Multicenter Post-Mortem Tissue Core and 
assisted in analysis of the immunohistochemical staining results. O.H.T. and M.G.H. analyzed the data. All authors contributed to the 
interpretation, writing, and editing of the manuscript.
DECLARATION OF INTERESTS
The authors declare no competing interests.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2019.09.066.
HHS Public Access
Author manuscript
Cell Rep. Author manuscript; available in PMC 2019 November 20.
Published in final edited form as:
Cell Rep. 2019 October 29; 29(5): 1164–1177.e5. doi:10.1016/j.celrep.2019.09.066.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
SUMMARY
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the 
progressive loss of motor neurons. While several pathogenic mutations have been identified, the 
vast majority of ALS cases have no family history of disease. Thus, for most ALS cases, the 
disease may be a product of multiple pathways contributing to varying degrees in each patient. 
Using machine learning algorithms, we stratify the transcriptomes of 148 ALS postmortem cortex 
samples into three distinct molecular subtypes. The largest cluster, identified in 61% of patient 
samples, displays hallmarks of oxidative and proteotoxic stress. Another 19% of the samples 
shows predominant signatures of glial activation. Finally, a third group (20%) exhibits high levels 
of retrotransposon expression and signatures of TARDBP/TDP-43 dysfunction. We further 
demonstrate that TDP-43 (1) directly binds a subset of retrotransposon transcripts and contributes 
to their silencing in vitro, and (2) pathological TDP-43 aggregation correlates with retrotransposon 
de-silencing in vivo.
Graphical Abstract
In Brief
Tam et al. present transcriptome profiling results from a large set of amyotrophic lateral sclerosis 
(ALS) patient cortex samples, finding 3 distinct groups. Two ALS subtypes are marked by gene 
pathways previously associated with ALS disease, while a third group shows elevated 
retrotransposon expression linked to TDP-43 pathology.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disorder with 
no known cure, and only two Food and Drug Administration (FDA)-approved treatments 
that appear to mildly slow disease progression. ALS is a largely sporadic disease, with 90% 
of patients carrying no known genetic mutation or family history of disease. Large-scale 
patient sequencing studies have identified a growing number of genes in which mutations 
are linked to ALS (Chia et al., 2018; Nicolas et al., 2018; van Rheenen et al., 2016). The 
most common ALS-associated mutations are repeat expansions in the intronic region of 
C9orf72, while mutations in well-known ALS-associated genes such as SOD1 and TARDBP 
are typically present in fewer than 2% of all ALS patients (Chia et al., 2018).
Mutations in the TARDBP gene (that generates the TDP-43 protein) are rare in ALS, yet 
nearly all ALS patients exhibit cytoplasmic aggregates of TDP-43 in the affected tissues 
(Arai et al., 2006; Neumann et al., 2006). TDP-43 has known roles in RNA splicing, 
stability, and small RNA biogenesis (Cohen et al., 2011). Recently, several studies have 
suggested that TDP-43 also plays a role in regulating the activity of retrotransposons (Chang 
and Dubnau, 2019; Krug et al., 2017; Li et al., 2015; Saldi et al., 2014). Retrotransposons, a 
subset of transposable elements (TEs), are genomic parasites capable of inserting new copies 
of themselves throughout the genome by a process called retrotransposition. Previous work 
from our lab and others has shown that TDP-43 represses retrotransposon transcripts at the 
RNA level in animal models of TDP-43 pathology (Krug et al., 2017; Li et al., 2012). 
However, a role for TDP-43 in general retrotransposon silencing has not been demonstrated, 
nor whether TDP-43 pathology in ALS patients correlates with retrotransposon de-silencing. 
Of note, prior studies have identified a link between retrotransposon expression and repeat 
expansion in another ALS-linked gene, C9orf72 (Prudencio et al., 2017). Finally, contrasting 
studies either failed to find an enrichment for elevated levels of the endogenous retrovirus 
HERV-K in a smaller sample of ALS tissues (Mayer et al., 2018) or suggested that TDP-43 
may activate HERV-K transcription rather than silencing this particular retrotransposon (Li 
et al., 2015). These studies left open the question of whether retrotransposon silencing is a 
conserved role for TDP-43 and whether retrotransposon de-silencing would be expected in 
human tissues with TDP-43 dysfunction.
Here, we show that robust retrotransposon de-silencing occurs in a distinct subset of ALS 
patient samples, and this is associated with TDP-43 dysfunction. Unbiased machine learning 
algorithms identified three distinct ALS patient molecular subtypes within the large ongoing 
sequencing survey by the NYGC ALS Consortium. These subtypes represented both ALS 
disease-implicated signatures as well as additional correlated pathways. The largest 
subgroup of patients (61%) showed evidence of oxidative and proteotoxic stress. A second 
subgroup (19%) displayed strong signatures of glial activation and inflammation. A third 
subgroup (20%) was marked by retrotransposon re-activation as a dominant feature. We 
further validated the correlation between TDP-43 pathology and retrotransposon de-
silencing in a second independent cohort of postmortem tissue samples, which also 
recapitulated the three distinct molecular subtypes. These subtypes may reflect different 
predominant aberrant cellular mechanisms contributing to ALS pathogenesis, and thus 
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suggest specific therapeutic strategies may have greater relevance to distinct sets of sporadic 
ALS patients.
RESULTS
Evidence for Distinct Molecular Subtypes in ALS Patient Samples
The NYGC ALS Consortium has gathered deeply sequenced transcriptomes from the frontal 
cortex of 77 ALS patients as well as 18 neurological and non-neurological controls (Figure 
1A). For some patients, multiple samples were taken from various regions of the frontal 
cortex, including motor cortex, such that 148 total transcriptomes were available from ALS 
patients, while 28 were from controls (176 samples in all) (Table S1A). Most of these 
patients presented with sporadic ALS disease (i.e., no known family history or pathogenic 
mutation) consistent with general estimates that ALS as a disease is largely sporadic (Chia et 
al., 2018).
The large size of this dataset enables de novo clustering algorithms to determine whether the 
ALS patient samples fall into distinct molecular subsets defined by specific gene signatures. 
We used a recent method for de novo clustering that was originally developed for single-cell 
sequencing datasets, but has been equally validated on bulk transcriptomes, single-cell RNA 
sequencing (RNA-seq) analysis and klustering evaluation (SAKE) (Ho et al., 2018). SAKE, 
developed by our group, is based on non-negative matrix factorization (NMF) and can 
robustly estimate both the number of clusters present in a given dataset and the confidence in 
assigning each sample to a cluster. SAKE returned optimal results for 3 clusters within the 
NYGC ALS Consortium Cohort (Figure S1), and a heatmap of the genes that define these 
clusters is given in Figure 1B. Based on the sets of gene markers returned by the SAKE 
algorithms, some of which are labeled on the left hand side of Figure 1B (see also Table 
S2A), we have chosen to re-label the 3 ALS subtypes as ALS-TE (elevated transposable 
element, or TE, expression, red in Figure 1B), ALS-Ox (oxidative stress markers, blue), and 
ALS-Glia (elevated glial markers, gold).
The largest subset of patient samples in the NYGC survey (91/148) were marked by elevated 
levels of several genes previously associated with ALS. These included NEFH, SOD1, and 
CDH13 (Chia et al., 2018), as well as a general expression signature consistent with 
oxidative and proteotoxic stress. These samples are identified as ALS-Ox (Figure 1B, blue). 
ALS-Ox patient samples showed elevated levels of genes in the oxidative phosphorylation 
pathway, in pathways associated with Parkinson’s disease, as well as proteotoxic stress 
pathways as determined by Gene Set Enrichment Analysis (GSEA) (Figure 1C; Table S2B). 
Surprisingly, these samples also showed enrichment for genes previously noted to be 
elevated in both mutant SOD1 (Chiu et al., 2013) and TREM2-dependent (Keren-Shaul et 
al., 2017) models of disease associated microglia (Figure 1C), although microglial markers 
were not specifically enriched in these samples (Table S2B).
A second subset of patient samples, dubbed ALS-Glial (Figure 1B, gold), is defined by 
increased expression of genes that mark astrocytes (CD44, GFAP) and oligodendrocytes 
(MOG, OLIG2) suggesting that glial markers were a dominant signature in the 
transcriptomes of these samples. The ALS-Glial subset of patient samples also showed 
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strong enrichment for transcriptional signatures previously identified as marking disease-
associated microglia in either a mutant SOD1 (Chiu et al., 2013) or TREM2-dependent 
model (Keren-Shaul et al., 2017) (Figure 1C; Table S2C) and in levels of TREM2 expression 
(Figure 1D). Finally, these patients also showed upregulation of innate immune pathways 
that are typically elevated in activated microglia, such as interferon and antigen processing 
pathways (Figure 1C).
Retrotransposon transcripts form a subset of the genes that define the remaining ALS 
samples, ALS-TE, named for transposable elements (TEs). These patient samples (Figure 
1B, red) represented 20% (29/148) of the samples in the NYGC cohort. The ALS-TE 
samples showed an enrichment for transposon expression as the most significantly enriched 
pathway relative to controls using GSEA pathway analysis (Figure 1C; Table S2D), and this 
included TEs from the long interspersed element (LINE), short interspersed element (SINE), 
and long terminal repeat (LTR) classes. The samples in the ALS-TE subset also showed 
depletion for components of the spliceosome and for protein export pathways, two pathways 
previously linked to normal TDP-43 function (Cohen et al., 2011). Finally, violin plots of 
individual transposable elements, such as the LINE element L1PA6, show increased 
transposon levels for specific retrotransposons (Figure 1D). The fact that unbiased and 
unsupervised clustering identified several individual TEs as specifically defining this group 
provides a rigorous and quantitative method of determining the samples in which TE 
expression is well above the normal control levels and unique to this subset of ALS patients.
As stated above, multiple frontal and motor cortex tissues were sampled for a subset of ALS 
patients, allowing for an estimation of the level of concordance of ALS subtype between 
different tissues for the same patient. Of the 40 patients with both frontal and motor cortex 
samples sequenced, we note that only 7 were discordant between the two tissues (17.5%), 
suggesting a high degree of overlap between these two tissues (Table S1B).
The ALS-Ox Group Displays Evidence of Oxidative Stress
The importance of oxidative stress in neurodegenerative disease began with the initial 
identification of superoxide dismutase 1 (SOD1) as the first ALS-associated mutation 
(Rosen et al., 1993). Subsequent studies have identified a diverse array of functional 
pathways altered in SOD1 mutant mouse models, including SOD1 mediated autophagy 
(Rudnick et al., 2017), proteotoxic stress (Bruijn et al., 1998), and neuroinflammation (Chiu 
et al., 2013), reflecting both the pleiotropic roles played by SOD1 protein as well as different 
manifestations depending on the cellular context in which SOD1 is dysfunctional. Since that 
initial discovery, several genes with roles in oxidative stress, proteotoxic stress, and 
autophagy have been linked to ALS (Taylor et al., 2016). Consistent with the importance of 
these pathways, and their linked nature in generating neuronal stress, we found that 61% of 
the NYGC ALS patient samples displayed gene expression signatures consistent with a 
robust response to oxidative and proteotoxic stress, as described below.
Samples in the ALS-Ox group show elevated levels of several stress response genes, 
mutations in which have been linked to ALS, including SOD1 itself (Figures 1D and 2A), as 
well as the neurofilament protein NEFL and the nuclear matrix protein MATR3 (Figure 2B). 
More generally, the pathways that are elevated in the ALS-Ox samples relative to controls 
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include genes involved in oxidative phosphorylation, proteasomal components, and genes 
involved in the unfolded protein response (Figure 2C). This subset of patients also displayed 
elevated expression of several genes that have been previously associated with multiple 
neurodegenerative diseases including both ALS and Parkinson’s disease, such that these 
disease pathways are also significantly enriched in the ALS-Ox group relative to controls 
(Figure 2C; Table S2B).
To further validate these results, we obtained fresh frozen motor cortex tissue for an 
additional set of 13 ALS patients and 6 non-neurological controls, provided by a tissue bank 
at the University of California, San Diego (UCSD) (Table S1C). Two biological replicate 
transcriptomes were sequenced from each patient and control tissue sample to ensure the 
results would be robust to within-patient heterogeneity. We note that the RNA-seq libraries 
for the UCSD cohort were prepared at a different site, using a different library preparation 
protocol (please see Method Details), and yet these patient datasets displayed similar 
groupings to those from the NYGC cohort. We quantitatively assigned these samples to each 
of the ALS subtype groups, by combining the two groups (NYGC and UCSD) into a single 
principal components analysis (PCA) (Figure 2D). Patients were assigned to a subtype based 
on the distance to each cluster centroid on the PCA graph, with most samples falling within 
the 95% confidence interval ellipse defining the NYGC group (Figure S2A). Two of the 13 
ALS patients from this UCSD cohort fell within the ALS-Ox group, with 2 samples plotted 
per patient to show concordance between biological replicates. Consistent with their 
classification, we noted that these patient samples also displayed similar expression patterns 
for all ALS-Ox marker genes, comparable to that seen in the NYGC samples (Figure S2B, 
gray bars). We next performed qPCR expression analysis on all UCSD patient samples for a 
selection of genes whose dysregulation characterized each of the three molecular subtypes 
(Figure S2C). While the number of patient samples here is small relative to the larger NYGC 
cohort, corresponding significant differences were validated for NEFL (p < 0.01) and ATG5 
(p < 0.03) compared to controls. BECN1 showed milder differences that did not reach 
statistical significance compared to controls (p < 0.3) but shows a similar trend relative to 
other ALS cortex samples as that seen in the larger NYGC survey (Figure S2C).
The relative positions on the PCA plot in Figure 2D represent the expression of genes 
underlying the oxidative and proteotoxic stress responses in both patient cohorts. This is 
confirmed by the individual PCA plots of specific marker genes in Figure 2E, in which the 
color intensity of each dot indicates the expression level. For the oxidative stress pathway, 
expression is shown for oxidation resistance 1 (OXR1) and thioredoxin (TXN). For the 
proteotoxic stress response pathway, expression is shown for ubiquilin-2 (UBQLN2) and 
beclin-1 (BECN1). Finally, for markers of autophagy, expression is shown for autophagy 
gene 5 (ATG5) and TANK binding kinase (TBK1). We note that these 3 pathways are 
typically linked, such that both oxidative stress and proteotoxic stress have been noted to 
induce an autophagic response in neurodegenerative disease (Wong and Holzbaur, 2015), 
consistent with these pathways showing elevation in the same subset of samples. Thus, these 
results are consistent with ALS patient samples in the ALS-Ox group mounting a robust 
response to several neuronal stressors, which may be concurrent in the tissue.
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The Predominance of Glial Markers in the ALS-Glia Group
Several recent studies have noted the important role that glial cells play in neurodegenerative 
disease. Astrocytes, cells that support neuronal function by providing nutrients and 
removing waste, have previously been shown to secrete neurotoxic factors when expressing 
ALS-associated mutations (Di Giorgio et al., 2007; Nagai et al., 2007). Microglia, the innate 
immune cells of the CNS, have been shown to become activated in several 
neurodegenerative diseases (Deczkowska et al., 2018), setting off a neuroinflammatory 
cascade that eventually results in motor neuron cell death. In the ALS Consortium Cohort, 
19% of the ALS patient samples showed extensive evidence of glial involvement, as 
discussed below.
Samples in the ALS-Glial subgroup show elevated expression of markers for all glial cell 
types, including astrocytes (CD44, GFAP), microglia (IBA1/AIF1, TREM2), and 
oligodendrocytes (OLIG1, OLIG2, MOG), as noted on the heatmap of Figure 3A. Violin 
plots are shown in Figure 3B for specific genes marking microglial (IBA1) and astrocyte 
(CD44) cell types in each of the ALS patient samples, with a particular enrichment in ALS-
Glial subtype patients (gold). In particular, some of the microglial markers most prominently 
elevated in these samples represent genes known to be expressed in activated microglia and 
associated with neurodegenerative disease, such as IBA1 (Figure 3B) and TREM2 (Figure 
1D). Consistent with this, pathway analysis of the genes that are upregulated in ALS-Glial 
samples relative to controls include mediators of the inflammatory response in general, the 
interferon response in particular, and other genes downstream of the tumor necrosis factor 
alpha (TNF-α) signaling pathway (Figure 3C). Two recent reports have identified gene 
expression signatures of disease-associated microglia (DAM) in mouse models of 
neurodegeneration carrying mutations in either SOD1 (Chiu et al., 2013) or TREM2 (Keren-
Shaul et al., 2017). These two DAM gene expression signatures were also strongly enriched 
in the ALS-Glia cortex samples relative to controls (Figure 3C; Table S2C).
One underlying mechanism that could explain profiles in the ALS-Glia samples is a relative 
loss of motor neurons, and/or increased presence of glial cells in these particular tissues. We 
used software designed to infer the relative composition of different cell types in bulk 
tissues, NeuroExpresso (Mancarci et al., 2017), to determine whether there was any 
evidence of differential cell type enrichment in the ALS-Glial samples. The NeuroExpresso 
results support this possibility, with estimates of cellular composition showing an increase in 
markers of activated microglia (p < 0.003) as well as oligodendrocytes (p < 0.002) and 
astrocytes (p < 0.02) (Figure S3A) relative to controls. These patients also showed the 
strongest signatures for relative loss of neuronal markers from both the pyramidal (p < 6.7e–
7) and GABAergic (p < 3.1e–5) classes. We next obtained formalin-fixed paraffin-embedded 
(FFPE) slides matched to 35 of the decedents included in the NYGC cohort. These included 
7 decedents from the ALS-Glia cluster, 9 decedents each from the ALS-TE and ALS-Ox 
clusters, and 6 controls. We performed immunohistochemistry for the microglial protein 
IBA1 (Figures 3F and S3B). While IBA1 marks all microglia (resting and activated), we 
note that activated microglia are distinguished by more intense IBA1 staining and have 
enlarged cell bodies (diameters of ~70 μm for activated versus ~30 μm for resting, Figure 
S3B). Using these parameters, we quantified activated microglia in cortical layer sections. 
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We find a spectrum in the rate of activated versus resting microglia in the cortex (Figure 
S3B) and found the highest rates of activated microglia in the cortex of decedent samples 
corresponding to the ALS-Glia cluster (Figure S3B). These moderate increases in activated 
microglia could be associated with neuronal cell loss in these tissues. To address this 
possibility, we measured cell density by counting all of the hematoxylin positive nuclei in 
each sample (Figure S3C). There were no significant differences between ALS subtypes and 
controls, and no decrease in cell number per mm2 in the ALS-Glia patients, in particular. 
This suggests that the ALS-Glia transcriptome patterns are driven by activated transcription 
of glial cell associated pathways rather than relative loss of neuronal cells.
In the UCSD tissue validation cohort, 4/13 ALS patient samples clustered with the NYGC 
ALS-Glial group, without strong evidence of transposon de-silencing or oxidative stress 
markers (gold markers labeled by patient ID in the PCA plot of Figure 3D). These samples 
also showed elevated levels of TREM2 and IBA1 expression, at levels similar to that in the 
NYGC samples (Figure 3E). Moreover, markers of oligodendrocytes were also strongly 
enriched in this group, including OLIG1 and MOG. Finally, astrocyte markers were also 
present in these ALS-Glia samples, but were largely absent from samples in the ALS-TE 
and ALS-Ox groups, with GFAP and CD44 shown as representatives (Figure 3E). Validation 
by qPCR in the UCSD cohort, confirmed a significant enrichment for ALS-Glia markers in 
these patients relative to controls (Figure S2C): TREM2 (p < 0.001), MOBP (p < 0.001), and 
IBA1 (p < 0.01).
The ALS-TE Group Displays Altered Expression of Genes in Multiple Pathways Linked to 
TDP-43
Sporadic ALS patients are known to show cytoplasmic accumulation and aggregation of 
TDP-43 protein (produced by the TARDBP gene) in the motor cortex and spinal cord, two 
tissues where motor neuron loss occurs (Arai et al., 2006; Neumann et al., 2006). Such 
TDP-43 pathology is thought to cause both a loss of the normal function of TDP-43 as well 
as aggregation associated detrimental impact. Thus, TDP-43 targets would be expected to be 
mis-regulated in ALS patients with TDP-43 pathology and an associated loss of TDP-43 
nuclear function. Previous studies have linked TDP-43 to roles in splicing, mRNA 
metabolism, and protein export (Cohen et al., 2011), as well as retrotransposon silencing 
(Krug et al., 2017; Li et al., 2012). Consistent with this last role, several retrotransposons 
from the endogenous retrovirus (ERV), LINE, and SINE-VNTR-Alu (SVA) class were 
selected as specifically marking the ALS-TE group (Figure 4A). High levels of individual 
retrotransposons, including TEs from the LINE and SVA class (Figure 4B), characterize this 
group, while retrotransposons in general formed the top enriched pathway in GSEA (Figure 
4C). Additional pathways depleted from the ALS-TE group are also consistent with 
previously identified functional roles for TDP-43, including protein export, the spliceosome, 
and proteasomal components (Figure 4C). Finally, we note that TARDBP expression levels 
are the lowest in the ALS-TE group overall (Figure 4B), which could be mediated by 
TDP-43 auto-regulation (Ayala et al., 2011) or other mechanisms.
We again turned to samples from the UCSD patient cohort for follow up analysis and 
validation. Seven UCSD ALS decedents fell within the ALS-TE group, with patient ID 
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marked in red on Figure 4D. Consistent with their PCA-based classification (Figure S2A), 
we noted that these UCSD patient samples also displayed elevated levels of TEs, comparable 
to that seen in the NYGC samples (Figure S2B). This was validated using qPCR for three 
specific retrotransposons that are known to be young and active in human genomes (Mills et 
al., 2007): the human specific LINE1 element (L1HS, p < 0.05) and two young SINE 
elements of the Alu class, AluYk12 (p < 0.001) and AluYa5 (p < 0.001) (Figure S2C).
To establish a more direct link between the ALS-TE group and TDP-43 pathology, we 
stained slides from both the NYGC and UCSD decedent samples described above with an 
antibody directed against phosphorylated TDP-43, which has been previously characterized 
to identify patients with TDP-43 pathology in ALS (Neumann et al., 2009). The ALS-TE 
samples with elevated TE expression levels and loss of known TDP-43 pathway genes are 
the most likely to show TDP-43 inclusion pathology in the frontal and motor cortex (p < 
0.035), as shown for representative fields in Figure 4E and quantified in Figure S3D. Control 
samples did not show evidence of pTDP-43 inclusions in the tissues analyzed (Figure S3D), 
and non-ALS-TE samples did not exhibit transcriptional patterns consistent with established 
TDP-43 regulated pathways (Tables S2B and S2C). Together, these results establish a 
correlation between TDP-43 dysfunction and transcriptional re-activation of retrotransposon 
sequences in ALS patient tissues. The underlying basis for this will be explored next.
TDP-43 Functions to Silence Retrotransposons
While pathways linked to oxidative stress and activated glia have previously been linked to 
ALS and other neurodegenerative diseases (Taylor et al., 2016), a potential role for 
retrotransposons in ALS is only recently emerging. As such, we used a genomics approach 
in neuronal-like cell lines to bolster the connection between retrotransposon expression and 
the function of the ALS associated protein TDP-43. TDP-43 is an RNA binding protein with 
two RNA recognition domains that recognize UGUGU repeat motifs present in thousands of 
cellular RNAs (Polymenidou et al., 2011; Tollervey et al., 2011). Previous TDP-43 studies 
using fly (Krug et al., 2017; Li et al., 2012) and human (Li et al., 2012) models to identify 
downstream targets of TDP-43 have suggested that retrotransposons may form a subset of 
TDP-43 targets, either directly or indirectly, but the extent and functional impact of this was 
not fully understood. To establish the subset of direct TDP-43 target genes and 
retrotransposons, we sequenced the RNAs bound to TDP-43 protein using an enhanced 
cross-linking and immunoprecipitation protocol (eCLIP-seq) (Van Nostrand et al., 2016) in 
human SH-SY5Y neuroblastoma cells. Peaks were called using a CLIP-seq analysis tool 
designed for handling repetitive reads, CLAM (Zhang and Xing, 2017). Results from two 
biological replicates of TDP-43 eCLIP libraries were merged and normalized to a cross-
linked, size-matched input control, resulting in 36,716 called peaks mapping to 5770 genes 
and 439 transposable elements (Figure 5; Tables S3A and S3B). Thirty-one percent of all 
peaks mapped to transposable elements generally (Figure 5B). However, 58% of the TE 
associated peaks mapped to the opposite strand, suggesting the TEs were providing 
regulatory sequence for the host gene, a phenomenon previously observed for other RNA 
binding proteins (Attig et al., 2018; Kelley et al., 2014; Zarnack et al., 2013). The remaining 
42%, which were directly bound to TEs in the sense orientation, can be grouped into three 
major families, encompassing LINE elements (5% of all called peaks), SINE elements (4% 
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of peaks), and LTR regions that include endogenous retroviruses (2%). Verification that 
these sequences were directly bound to TDP-43 protein was supported by the presence of 
TDP-43 binding motifs at called peaks in both the gene and retrotransposon annotated peaks 
(Figure 5C; Table S3C). Examples of TDP-43 CLIP reads over a known gene target 
(TARDBP/TDP-43) as well as retrotransposon targets from each major class (LINE, L1PA6; 
SINE, AluY; LTR, HERV3; SVA, SVA_D) can be seen in Figured 5A and 5D with a full list 
in Table S3B. The gene targets correlate well with previously identified TDP-43 targets from 
CLIP-seq and RIP-seq studies (Colombrita et al., 2012; Polymenidou et al., 2011; Tollervey 
et al., 2011; Van Nostrand et al., 2016; Xiao et al., 2011), which previously missed 
transposon targets due to masking of repetitive regions or discarding of ambiguously 
mapped reads. Together, these results demonstrate that TDP-43 normally binds broadly to 
both gene and TE-derived transcripts. This comprehensive list of direct targets in SH-SY5Y 
cells provides a platform to investigate the impact of TARDBP knock down on expression of 
target RNAs.
To determine the subset of CLIP targets that are regulated at the transcript abundance level, 
we knocked down the levels of TDP-43 protein using a short hairpin RNA strategy 
(TDP-43kd). The TDP-43kd construct strongly reduced TARDBP mRNA expression and 
TDP-43 protein level (Figure 5G). We sequenced the transcriptomes of both control and 
TDP-43kd libraries. All significantly altered retrotransposon transcripts were upregulated in 
TDP-43kd cells, indicating that TDP-43 normally contributes to the silencing of 
retrotransposon transcripts (Figure 5E; Table S3D). This is in contrast to altered gene 
transcripts, where a substantial fraction was either up- (1,165 genes, 34%) or downregulated 
(2,246 genes, 66%) in TDP-43kd cells (Figure 5F; Table S3D). Moreover, a majority of the 
directly bound gene targets were downregulated in the absence of TDP-43 (52%). This is 
consistent with known roles for TDP-43 in contributing to alternative splicing or translation 
control for a large fraction of gene targets that are not regulated at the mRNA abundance 
level (Polymenidou et al., 2011; Tollervey et al., 2011). However, the fact that nearly all 
expressed retrotransposon transcripts were upregulated in the absence of TDP-43 suggests 
that TDP-43 plays a silencing role for transposons. This is consistent with previous studies 
of the role of TDP-43 in the fly brain (Krug et al., 2017) and conclusively link directly 
bound TDP-43 transposon targets with the regulation of these targets at the expression level.
Clinical Parameter Association with ALS Subtype
We investigated whether clinical/phenotypic variables correlate with the three ALS 
molecular subtypes identified in this study. As shown in Figure S4, there was no statistically 
significant association between any of the groups and sex, C9ORF72 repeat expansion 
status, age at death, age at onset, or disease duration. Patients with limb onset were more 
frequently associated with the ALS-TE subtype than expected (Fisher’s exact p < 0.03), 
however, there was no relative depletion of ALS-TE patient samples among those with 
bulbar onset symptoms. No significant differences in overall survival were found between 
the identified subtypes, as shown by Kaplan-Meier survival curves for each group (Figure 
S4G).
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Genotyping was performed to assess the distribution of patients carrying germline repeat 
expansions in C9orf72. Hexanucleotide repeat expansions in the intron of C9orf72 are the 
most common pathogenic alterations associated with the development of ALS, both familial 
and sporadic (Majounie et al., 2012). Moreover, previous studies have noticed a slight trend 
toward higher TE expression in patients carrying C9orf72 mutations (Pereira et al., 2018; 
Prudencio et al., 2017; Zhang et al., 2019). In order to determine if patients carrying a 
C9orf72 repeat expansion are overrepresented in one or several of the identified ALS 
subtypes, genotyping of the hexanucleotide repeat size was performed on the NYGC cohort 
(Table S1B). C9orf72 repeat expansion carriers were neither significantly over- nor 
underrepresented in the ALS-TE (p = 1) or ALS-Glia patients (p < 0.65). However, we 
observed a non-significant trend toward exclusion of C9orf72 repeat expansion carriers 
among the ALS-Ox samples (p < 0.09). We note that none of the patient samples from the 
UCSD validation cohort carried repeat expansions in C9orf72 (Table S1C), although each of 
the ALS subtypes was represented in this group (Figure S2B; Table S1C). Together, this 
suggests that C9orf72 repeat expansions are not driving the transcriptional profiles of these 
subgroups but may be associated with patterns typically not seen in patients of the ALS-Ox 
group.
DISCUSSION
De novo discovery of transcriptome subtypes from a large ALS cortex tissue sequencing 
study demonstrated that ALS cortex samples fall into three distinct clusters. The pathways 
that define two of these subtypes (oxidative and proteotoxic stress and neuroinflammation) 
have a well-established association with ALS disease, while a third subtype showed highly 
elevated retrotransposon expression. While genetic mutations are rare in ALS disease, 
pathogenic mutations can be grouped generally into those that largely mediate protein 
homeostasis, RNA metabolism, and neuroinflammation (Taylor et al., 2016), although many 
genes are linked to more than one of these processes. An example is SOD1, which has been 
ascribed roles in oxidative stress (Rosen et al., 1993), proteotoxic stress (Bruijn et al., 1998), 
and microglial activation (Chiu et al., 2013). While multiple cellular stressors might be 
contributing to the disease, we found that each decedent sample could be grouped into one 
of three molecular clusters, which largely reflected pathways already described for ALS, but 
which fell into surprisingly distinct groups. Specifically, 60% of the patient samples 
exhibited gene expression markers suggesting oxidative stress and proteotoxic stress were 
the main contributors to cellular dysfunction (the ALS-Ox group) but did not show elevated 
markers of glial cell types or inferred glial cell enrichment in the tissue downstream of these 
stress responses. Only 20% of the patients showed extensive glial involvement (the ALS-
Glial group), with an unknown mechanism initiating the activation of glial cells for these 
patients in particular.
The role of transposable element expression is a relatively new topic in the study of 
neurodegeneration. Moreover, the connection between TDP-43 and transposable elements 
has only recently been explored. While previous studies have linked TDP-43 to transposon 
binding in human cells and to transposon regulation in animal models (Chang and Dubnau, 
2019; Krug et al., 2017; Li et al., 2015; Liu et al., 2019), we show that TDP-4-bound 
transposon transcripts are de-silenced in human cells and demonstrate that these same targets 
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are de-silenced in a subset of human ALS patients. Additional mechanisms for transposon 
de-silencing in ALS patients with C9orf72 repeat expansions have been suggested (Pereira 
et al., 2018; Prudencio et al., 2017; Zhang et al., 2019), although we note that C9orf72 status 
was not strongly associated with the ALS-TE group in this study. Together, this suggests a 
model where retrotransposon silencing is a normal function of TDP-43 in somatic cells, and 
this role is disrupted in ALS patient tissues, potentially contributing to cellular toxicity. 
Previous studies have demonstrated that expression of envelope proteins from the 
endogenous retrovirus class of retrotransposons can be toxic to cells of the CNS (Antony et 
al., 2004; Kremer et al., 2013; Li et al., 2015). Additional studies have shown that expressed 
retrotransposon RNAs can also be toxic through aberrant recognition by innate immune 
components in Aicardi-Goutières syndrome (Crow and Manel, 2015). Other studies linked 
transposon activation in Alzheimer’s disease with tau aggregation and suggest these 
alterations accompany neuroinflammation and genomic instability (Guo et al., 2018; Sun et 
al., 2018). DNA damage and structural variants induced by transposition itself are a formal 
possibility, given the elevated levels of the fully competent LINE-1Hs retrotransposon and 
evidence for active L1Hs transposition in human neurons (Evrony et al., 2016; Upton et al., 
2015). However, most of the retrotransposons expressed in this study derived from fixed 
elements that have lost the capacity to transpose. These and other mechanisms for 
retrotransposon contributions to cellular toxicity remain to be explored in ALS patients but 
present a possible mechanism for cellular damage in the subset of patients with extensive 
TDP-43 pathology and retrotransposon re-activation.
Finally, the three subgroups defined in this study were identified from postmortem tissues of 
a largely sporadic set of patients with no known family history of the disease. Thus, ALS 
subtype appears to be largely independent from genotype. Transcriptional differences that 
separate these subtypes may reflect multiple contributing factors including causal 
mechanisms, disease progression stage, cellular composition of the tissues due to loss of 
particular cell types, and differences in environmental interactions that contribute to onset. 
The fact that transcriptional profiles of post mortem cortex tissues segregate into three 
distinct groupings may provide an entry point to investigate these underlying mechanisms. If 
peripheral tissues amenable to sampling or biopsy (e.g., peripheral blood monocytes, 
cerebrospinal fluid, or muscle) have distinct molecular signatures that correlate with patterns 
found in these CNS tissue subgroups, it could facilitate cohort selection for clinical trials of 
therapies targeting specific pathogenic mechanisms. Indeed, the existence of distinct clusters 
of sporadic ALS patients—whether based on intrinsic pathogenic differences or disease 
stage—might explain why many treatments identified in laboratory models targeting a 
specific pathway have failed to translate to successful clinical trials. Additional correlations 
may arise as the ALS Consortium genomic data cohort continues to grow. These additional 
studies will allow for an exploration of whether glial activation in the CNS correlates with 
general inflammation outside of CNS tissues.
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STAR★METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Immediate access to new and ongoing data generated by the NYGC ALS Consortium and 
obtained from samples collected through the Target ALS post-mortem core can be requested 
at ALSData@nygenome.org. All RNA-seq data in the NYGC ALS Consortium are made 
immediately available to all members of the Consortium and with other Consortia with 
whom we have a reciprocal sharing arrangement. Further information and requests for 
resources and reagents generated outside of the NYGC ALS Consortium should be directed 
to Molly Gale Hammell (mhammell@cshl.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
ALS Post-mortem Samples—The NYGC ALS Consortium samples in this study, the 
majority provided by the Target ALS Post-Mortem Tissue Core, were acquired through 
various IRB protocols from member sites and transferred to NYGC in accordance with all 
applicable foreign, domestic, federal, state, and local laws and regulations for processing, 
sequencing, and analyses. All available de-identified clinical and pathological records were 
collected and used together with C9orf72 genotypes to summarize patient demographics and 
disease features (see Tables S1A and S1B).
UCSD samples were obtained from patients who had been followed during the clinical 
course of their illness and met El Escorial criteria for definite ALS. These individuals had 
bulbar or arm onset of disease and caudally progressing disease. Control nervous systems 
were from patients from the hospital’s critical care unit when life support was withdrawn. 
IRB approval was obtained from the University of California, San Diego Human Research 
Protection Program. All available de-identified patient data is available in Table S1C.
Cell Line—SH-SY5Y cells (CRL-2266, ATCC, Manassas, VA, USA) were grown in 
DMEM/F-12 Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (11320033, 
ThermoFisher Scientific, Waltham, MA, USA) supplemented with 10% FBS and 1% 
penicillin–streptomycin, and cultured at 37°C with 5% CO2.
HEK293FT cells (R70007, ThermoFisher Scientific, Waltham, MA, USA) were grown in 
DMEM medium containing 10% FBS, and cultured at 37°C with 5% CO2.
METHOD DETAILS
Generation of RNA-seq Libraries from NYGC ALS Samples—RNA was extracted 
from flash-frozen patient samples homogenized in Trizol (15596026, ThermoFisher 
Scientific, Waltham, MA, USA) -Chloroform and purified using the QIAGEN RNeasy Mini 
kit (74104, QIAGEN, Germantown, MD, USA). RNA was assessed using the Bioanalyzer 
(G2939BA, Agilent, Santa Clara, CA, USA). RNA-seq libraries were prepared from 500 ng 
of total RNA using the KAPA Stranded RNA-seq kit with RiboErase (07962304001, Kapa 
Biosystems, Wilmington, MA, USA) for rRNA depletion and Illumina compatible indexes 
(NEXTflex RNA-seq Barcodes, NOVA-512915, PerkinElmer, Waltham, MA, USA). Pooled 
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libraries (average insert size: 375bp) were sequenced on an Illumina HiSeq 2500 using a 
paired end 125 nucleotide setting, to yield ~40–50 million reads per library.
Generation of RNA-seq Libraries from UCSD ALS Samples—RNA was extracted 
from each of the flash-frozen patient samples using the Ambion PureLink RNA Mini kit 
(12183020, ThermoFisher Scientific, Waltham, MA, USA). RNA was assessed using the 
Bioanalyzer to ensure RNA Integrity (RIN) values of > = 5.5. RNA-seq libraries were 
prepared from 500 ng of total RNA using the Illumina TruSeq Stranded Total RNA kit 
(20020596, Illumina, San Diego, CA, USA). Samples were barcoded to multiplex 8 samples 
per batch, randomly mixing ALS and control samples in each library preparation and 
sequencing batch. The libraries were sequenced on an Illumina NextSeq using a single end 
76 nucleotide setting, and pooled to ensure ~40 million reads per library.
shRNA Knockdown and Assessment of Efficiency—The MISSION pLKO.1-puro 
human TDP-43 (TRCN0000016038, Genetic Perturbation Platform) and control shRNAs, 
SHC007 luciferase shRNA and SHC016 Non-target shRNA control (Sigma Aldrich, St. 
Louis, MO, USA), were used to produce lentivirus. The pLKO.1 plasmid DNA, together 
with psPAX2 packaging and pMD2.G envelope plasmid DNA (Didier Trono lab, Addgene 
plasmid # 12260 and 12259 respectively) were combined at a ratio of 4:3:1, respectively and 
transfected with PEI reagent (23966-1, Polysciences, Warrington, PA, USA) into 
HEK293FT cells. Virus containing medium was collected 48 and 72 hours post-transfection 
and stored at −80° C.
One and a half to two million SH-SY5Y cells per well of a 6-well plate were “spinfected” 
with 3 mL of virus containing media and 8μg/mL polybrene for 1 hour at 800 g. Cells stably 
expressing shRNAs were selected with 2 μg/mL of puromycin 48 hours post-infection for 3 
days. Uninfected cells at similar density were used as a control for puromycin selection. 
Cells were harvested 5 days after infection for downstream analyses.
TDP-43 protein level was assessed by western blot analysis on two biological replicates of 
SH-SY5Y cells treated with the TDP-43kd construct or control shRNAs (SHC007 luciferase 
shRNA or SHC016 Non-target shRNA control) as described above. In brief, 15 μg of protein 
was electrophoresed on a Bolt 4%–12% Bis-Tris Plus Gel (NW04120BOX, ThermoFisher 
Scientific, Waltham, MA, USA), and transferred to nitrocellulose membrane. Primary 
antibodies specific for TDP-43 (10782-2-AP, Proteintech, Rosemont, IL, USA, 1:3,000), 
alpha-tubulin (Clone DM1A, provided by the CSHL monoclonal antibody collection, Cold 
Spring Harbor, NY, USA, 1:3000) and GAPDH (5174, Cell Signaling Technology, Danvers, 
MA, USA, 1:1000) were used. Protein detection was performed using HRP-linked 
secondary antibodies (7074 and 7076, Cell Signaling Technology, Danvers, MA, USA, 
1:10000), and Super Signal West Pico PLUS Chemiluminescent Substrate (34577, 
ThermoFisher Scientific, Waltham, MA, USA).
Knockdown efficiency of TARDBP transcript was assessed by quantitative PCR, performed 
in triplicate on two biological replicates of SH-SY5Y cells treated with the TDP-43kd 
construct or control shRNAs (SHC007 luciferase shRNA or SHC016 Non-target shRNA 
control) as described above. Total RNA was extracted using Trizol according to the 
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manufacturer’s instructions from the harvested cells. qPCR reactions were made with the 
PowerUp SYBR Green Master Mix according to the manufacturers’ instructions (A25741, 
ThermoFisher Scientific, Waltham, MA, USA), and run on a QuantStudio 6 Flex instrument 
(ThermoFisher Scientific, Waltham, MA, USA). Primers for TARDBP and GAPDH were 
obtained from PrimerBase (Spandidos et al., 2010). Please see Table S4 for more details on 
the primers used.
RNA-seq in SH-SY5Y Cells—Total RNA was extracted using Trizol according to the 
manufacturer’s instructions from two biological replicates of SH-SY5Y cells treated with 
the TDP-43kd construct or control shRNAs (SHC007 luciferase shRNA or SHC016 Non-
target shRNA control) as described above. One microgram of total RNA was subjected to 
rRNA removal using the Ribo-Zero Gold rRNA Removal kit (MRZG126, Illumina, San 
Diego, CA, USA). Strand specific RNA-seq libraries were constructed using NEBNext Ultra 
II Directional Library Prep Kit (E7760S, New England Biosciences, Ipswich, MA, USA). 
The libraries were sequenced on an Illumina NextSeq using a single end 76 nucleotide 
setting, and pooled to ensure ~40 million reads per library.
TARDBP/TDP-43 eCLIP in SH-SY5Y Cells—Twenty million SH-SY5Y cells were UV-
crosslinked (254 nm, 400 mJ/cm2) in PBS and cell pellets were stored at −80°C. Each 
sample was prepared as an independent biological replicate and included non-crosslinked 
cells as a control. Cell pellets were lysed in 1 mL lysis buffer, followed by RNase I digestion 
and immunoprecipitation with 10 μg of anti-TDP-43 antibody (10782-2-AP, Proteintech, 
Rosemont, IL, USA).
eCLIP libraries were prepared as previously described (Van Nostrand et al., 2016). In brief, a 
barcoded adaptor is ligated to the 3′ end, and the precipitated RNA-protein complex is 
separated on nitrocellulose. The complex is digested with proteinase K and the RNA is 
precipitated and reverse-transcribed using SuperScript IV first strand synthesis system 
(18091050, ThermoFisher Scientific, Waltham, MA, USA). A second adaptor is ligated on 
the 5′ end, and the libraries were sequenced on an Illumina NextSeq500 using a single end 
76 nucleotide setting.
Histology and Immunohistochemistry—Frozen motor cortex tissues were fixed in 
10% neutral buffered formalin and 5 μm paraffin sections were cut for 
immunohistochemistry (IHC) staining. IHC staining was performed on Ventana Discovery 
Ultra platform with OmniMap HRP and ChromoMap DAB detection system according to 
manufacturer’s protocols (Roche, Indianapolis, IN, USA), using primary antibodies specific 
for TDP-43 (10782-2-AP, Proteintech, Rosemont, IL, USA, 1:10,000), phosphoTDP-43 
(pS409/410) (CAC-TIP-PTD-M01, Cosmo Bio USA, Co., Carlsbad, CA, 1:200) and IBA1 
(RPCA-IBA1, EnCor Biotechnology Inc., Gainesville, FL, 1:2,000). Slides were 
counterstained with Hematoxylin, and then scanned by Leica Aperio ScanScope system.
Genotyping of C9orf72 Repeat Expansion—NYGC patient samples were genotyped 
for C9orf72 repeat expansions using a combination of cross-repeat fragment size analysis, 
standard repeat-primed PCR, and the Asuragen AmplideX PCR/CE C9ORF72 Kit (49581, 
Asuragen, Austin, TX, USA).
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UCSD patient samples were genotyped for C9orf72 repeat expansions using standard repeat-
primed PCR, as previously described (Renton et al., 2011). Briefly, primers outside the 
C9orf72 intronic repeats were amplified in a nested PCR strategy, and the resulting traces 
were analyzed on a Bioanalyzer to determine repeat length.
qPCR Analysis of UCSD Patient Samples—Quantitative PCR of UCSD samples was 
carried out in triplicate on two biological replicates each, using PowerUp SYBR Green 
Master Mix according to the manufacturers’ instructions (A25741, ThermoFisher Scientific, 
Waltham, MA, USA), and run on a QuantStudio 6 Flex instrument (ThermoFisher Scientific, 
Waltham, MA, USA). Primers for AIF1/IBA1, ATG5, BECN1, GAPDH, MOBP, NEFL and 
TREM2 were obtained from PrimerBank (Spandidos et al., 2010). Primers for RPS24 were 
obtained from Sigma Aldrich (H_RPS24_1, Sigma Aldrich, St. Louis, MO, USA). 
Previously published primers for L1HS 5′ UTR (Macia et al., 2017), AluYa5 and AluYk12 
(Prudencio et al., 2017) were used for quantification of these transposable elements.
Please refer to Table S4 for more details on the primers used.
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis of RNA-seq Libraries—Reads from samples with RIN > = 5.5 were aligned to 
the hg19 human genome using STAR v2.5.2b (Dobin et al., 2013), allowing for a 4% 
mismatch rate and up to 100 alignments per read to ensure capture of young transposon 
sequences. Abundance of gene and transposon sequences was calculated with TEtranscripts 
v2.0.3 (Jin et al., 2015). For differential expression analysis, we employed DESeq2 (Love et 
al., 2014), using the DESeq normalization strategy and negative binomial modeling. B-H 
corrected FDR P value threshold of p < 0.05 was used to determine significance. For 
heatmap visualization, the reads were normalized using a variance stabilizing transformation 
in DESeq2.
Transcriptome De Novo Cluster Identification—The number of clusters in the ALS 
datasets was determined using the SAKE software suite (Ho et al., 2018). Briefly, a variance 
stabilizing transformation was performed on the raw counts data using DESeq2. Gender 
associated genes were then removed from this list before rank ordering by median absolute 
deviation using the SAKE software suite, selecting the top 5000 genes with the highest 
median absolute deviation (MAD). SAKE was implemented using 200 iterations, the 
“nsNMF” algorithm for Non-negative Matrix Factorization, and a “k” setting of 3 clusters 
for the cortex samples, determined by the k setting with the highest cophenetic correlation 
coefficient. Wilcoxon Mann Whitney U-tests were used to determine differences between 
ALS Subgroups and correlations with gene expression or cell type composition.
Classification of UCSD Samples using NYGC-identified Clusters—Variance 
stabilizing transformation was performed on the raw counts of NYGC and UCSD data using 
DESeq2. Principal component analysis was then performed to identify principal components 
that delineate the identified ALS subtypes, and a 95% confidence ellipse was calculated 
from the NYGC samples for each subtype. The position of the UCSD patient samples along 
the principal components of interest was determined as the midpoint of the two replicates, 
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and a distance to the center of the 95% confidence ellipse for each subtype was calculated. 
The UCSD samples were classified based on the nearest ellipse center of the subtype.
Gene Set Enrichment Analysis—Pre-generated gene sets used for GSEA (Subramanian 
et al., 2005) were obtained from the MSigDB Hallmark collection (Liberzon et al., 2015), 
and KEGG (Kanehisa and Goto, 2000). Custom gene sets were generated from the SOD1 
(Chiu et al., 2013) and TREM2 (Keren-Shaul et al., 2017) models of disease-associated 
microglia, as well as TARDBP targets from this study. Custom transposable element sets, 
including retrotransposons considered active in the human genome (Mills et al., 2007) were 
generated from Repbase (Bao et al., 2015).
Analysis of eCLIP Libraries—Reads were trimmed to remove adapters, and aligned to 
the hg19 human genome using STAR v2.5.2b (Dobin et al., 2013), allowing for a 4% 
mismatch rate and up to 100 alignments per read to ensure capture of young transposon 
sequences. Weighting of multi-mapper alignments (expectation-maximization modeling) and 
identification of regions of enrichment relative to input (using negative binomial modeling) 
were performed with CLAM v1.1.3 (Zhang and Xing, 2017). Detected sites with B-H 
corrected FDR P value of p < 0.05 were considered to be significantly enriched. Integrated 
genome viewer (Robinson et al., 2011) was used for visualization of enriched regions and 
read depth.
Analysis of IHC Tissue Slides—Images were exported from the Leica Aperio 
ScanScope and analyzed using the QuPath image analysis software v 0.2.0-m2 (Bankhead et 
al., 2017). Upper cortical regions within 1.5mm of the outer cortical surface of the tissue that 
were of good quality (minimal damage or non-specific staining) were chosen as regions of 
interest. Cell nuclei were detected in the regions of interest using Hematoxylin optical 
density (minimum nuclear area of 15μm2, but otherwise default settings). Cells positive for 
phosphorylated TDP-43 accumulation were identified as having mean nuclear DAB optical 
density above 0.75. Activated microglia were designated as cells with nuclear area of at least 
70μm2, and a mean nuclear DAB optical density above 0.7. Proportions of positive cells 
(pTDP-43 or activated microglia) were calculated. Cell density in regions of interest was 
determined by dividing the number of detected nuclei by the area of the regions of interest. 
Wilcoxon Mann Whitney U-tests were used for comparison of pTDP-43/IBA1 positive cell 
proportions and cell density between ALS Subgroups and control samples.
qPCR Data Analysis—Quantitative PCR results of UCSD patient samples were analyzed 
using the ΔΔCt method, normalized to GAPDH and RPS24. Knockdown efficiency of 
TDP-43kd construct was determined using the ΔΔCt method, normalized to GAPDH. 
TARDBP transcript levels are expressed relative to the SHC007 transfected samples. A 
Student’s t test was used to determine statistical significance.
Analysis of Clinical Parameters—Fisher’s Exact test was used to determine 
enrichments of patient gender and C9orf72 repeat expansion in each ALS subtype. 
Differences in age of death (compared to control individuals), age of onset and disease 
duration (compared between subtypes) was analyzed using Wilcoxon Mann Whitney U-
tests. Survival analysis was performed using Kaplan-Meier log rank test.
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DATA AND CODE AVAILABILITY
The accession number for the CSHL Motor Cortex RNA-seq datasets reported in this paper 
is GEO: GSE122649. The accession number for the CLIP-seq and RNA-seq datasets from 
SH-SY5Y cells reported in this paper is GEO: GSE122650. The accession number for the 
RNA-seq datasets generated by the NYGC ALS Consortium reported in this paper is GEO: 
GSE124439.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGMENTS
We wish to thank Y. Jin for helpful discussions, the Target ALS Human Postmortem Tissue Core for providing post-
mortem brain samples and slides, the CSHL Sequencing Facility (supported by an NIH Cancer Center support grant 
5P30CA045508) for additional sequencing support, the CSHL Histology Core Facility (partially supported by NIH 
support grant 5P30CA045508) for performing the histology and IHC staining, the CSHL monoclonal antibody 
collection (supported by an NIH Cancer Center support grant 5P30CA045508) for the anti alpha-tubulin mouse 
monoclonal antibody (clone DM1A), and the Harms laboratory for performing repeat-primed PCR to identify 
C9ORF72 expansions in the Target ALS samples. Schematic images were adapted with permission from Servier 
Medical Art (https://smart.servier.com). This work was supported by grants from the Chan Zuckerberg Initiative 
(DAF2018-191863), the Ride For Life Foundation, the Rita Allen Foundation of which M.H. is a scholar, the 
O’Neil Charitable Trust, the NIH/NINDS (5R21NS088449 and R01NS091748), and the NIH/NIA 
(R01AG057338). All NYGC ALS Consortium activities are supported by the ALS Association (15-LGCA-234) 
and the Tow Foundation.
Appendix
CONSORTIA
The members of the NYGC ALS Consortium include Hemali Phatnani, Justin Kwan, Dhruv 
Sareen, James R. Broach, Zachary Simmons, Ximena Arcila-Londono, Edward B. Lee, 
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Highlights
• ALS patient cortex samples can be grouped into 3 distinct expression profiles
• Aberrant pathways include stress, inflammation, and TDP-43 pathology
• Elevated retrotransposon expression is correlated with TDP-43 pathology
• TDP-43 directly binds retrotransposons in cells and contributes to their 
silencing
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Figure 1. ALS Patients in the NYGC ALS Consortium Cohort Show 3 Distinct Subtypes: 
Retrotransposon Reactivated (ALS-TE), Oxidative Stress Signatures (ALS-Ox), and Glial 
Dysfunction (ALS-Glial)
(A) A schematic depiction of cortical regions from which post-mortem tissue samples were 
obtained: 148 from ALS patients, 11 from patients with other neurological disorders, and 17 
from subjects. Multiple samples were obtained for most patients, such that these samples 
represent 77 ALS patients, 6 neurological control subjects, and 12 healthy controls.
(B) A heatmap of gene expression in ALS patient samples showing the results of NMF-
based clustering, which returned 3 robust and distinct groups of patients. The 
retrotransposon reactivated set showed high TE expression as a dominant signature and 
formed its own subgroup (ALS-TE), representing 20% of all patient samples. Two additional 
groups were identified that showed signatures of oxidative stress (ALS-Ox, 61% of 
samples), and glial dysfunction (ALS-Glial, 19% of samples). Representative gene sets that 
describe markers from each subset are identified along the left of the heatmap.
(C) Gene Set Enrichment Analysis was performed for each group of patients (ALS-TE, 
ALS-Ox, and ALS-Glial) versus controls to identify group-specific aberrant pathways.
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(D) Violin plots of example markers for each group show the LINE retrotransposon L1PA6 
marking the ALS-TE group, SOD1 marking the ALS-Ox group, and TREM2 marking the 
ALS-Glial samples.
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Figure 2. ALS-Ox Patients in the NYGC ALS Consortium Show Markers of Oxidative Stress
(A) The ALS-Ox group represents the middle 61% of patient samples in the ALS 
Consortium set (outlined in blue), with ALS-Ox marker genes listed along the left-hand side 
of the heatmap.
(B) Violin plots of example markers for this group show two known ALS-associated genes, 
MATR3 and NEFL, specifically elevated in the ALS-Ox group (blue violins).
(C) Top enriched pathways identified by GSEA in the ALS-Ox group samples compared to 
controls.
(D) Additional ALS patient samples from UCSD are assigned to the NYGC ALS subgroups 
by position on this PCA plot (UCSD samples marked by patient ID in blue).
(E) To confirm the link between ALS-Ox membership and stress pathways, individual PCA 
plots are shown where each sample is colored by the normalized expression of genes in the 
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Oxidative Stress pathway (OXR1, TXN), ER-linked proteotoxic stress pathways (UBQLN2, 
BECN1 and downstream genes related to autophagy (ATG5, TBK1).
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Figure 3. ALS-Glia Patients in the NYGC ALS Consortium Cohort Show Evidence of Disease-
Associated Microglia
(A) The ALS-Glia group represents the 19% of patient samples on the right side of the ALS 
Consortium set (outlined in gold), with additional ALS-Glia marker genes listed along the 
left side of the heatmap.
(B) Violin plots of example markers for this group show two known glial marker genes, 
AIF1/IBA1 and CD44, specifically elevated in the ALS-Glia group (gold violins).
(C) Top enriched pathways identified by GSEA in the ALS-Glia group samples compared to 
controls.
(D) Additional ALS patient samples from UCSD are assigned to the NYGC ALS subgroups 
by position on this PCA plot (UCSD samples marked by patient ID in gold).
(E) To confirm the link between ALS-Glia membership and markers of particular glial 
subsets, individual PCA plots are shown where each sample is colored by the normalized 
expression of genes that mark Microglia (IBA1, TREM2), Oligodendrocytes (OLIG1, 
MOG), and astrocytes (GFAP, CD44).
(F) To confirm the link between ALS-Glia membership and activated microglia, UCSD 
patient samples were stained with antibodies to IBA1. ALS-Glia samples show presence of 
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enlarged, activated microglia not seen in controls or other ALS subgroups. Images are 
shown at 20 × magnification, with labeled scale bars indicating a size of 50–70μm.
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Figure 4. ALS-TE Patients in the NYGC ALS Consortium Cohort Show Retrotransposon Re-
activation
(A) The ALS-TE group represents the left hand 20% of patients in the ALS Consortium 
sample set (outlined in Red), with ALS-TE markers listed along the left-hand panel.
(B) Violin plots of example markers for this group show two relatively young 
retrotransposons, L1HS and SVA_A, and TARDBP expression.
(C) Top enriched pathways identified by GSEA in the ALS-TE versus controls.
(D) Additional ALS samples from UCSD are assigned to the defined subgroups by position 
on this PCA plot (UCSD samples marked by patient ID in red).
(E) To confirm the link between ALS-TE membership and TDP-43 pathology, UCSD patient 
samples were stained with antibodies to the phosphorylated form of TDP-43 (pTDP-43, left) 
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as well as with antibodies that recognize full-length TDP-43 protein (right). ALS-TE 
samples show evidence of pTDP-43 pathology not present in controls or other ALS 
subgroups. Images are shown at 20 × magnification, with labeled scale bars indicating a size 
of 50μm.
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Figure 5. TDP-43 Binds and Regulates Retrotransposon Transcripts
(A) A schematic of the eCLIP-seq based identification (2 biological replicates) of directly 
bound RNA targets for TDP-43, with a representative pileup of reads where TDP-43 is 
known to target its own 3′ UTR.
(B) A pie chart of annotation categories for TDP-43 targets shows that retrotransposons are a 
small but important fraction of direct targets (12.9%). Gene intronic sequences represent the 
largest fraction of all peaks at 44%, while an additional 17.6% represent regions where TEs 
provide regulatory sequences to the host gene intron.
(C) The known TDP-43 binding motif (UGUGU) is present in both gene and 
retrotransposon targets.
(D) Representative browser pileup plots for one retrotransposon from each major repeat 
class: an L1PA6 LINE element, an AluY SINE element, a HERV3 LTR element, and an 
SVA_D from the human specific SVA class.
(E) Knock down of TDP-43 levels (2 biological replicates) results in the upregulation of 
retrotransposon transcripts, most of which also show evidence for direct binding in the 
eCLIP-seq experiments (gray bars).
(F) A volcano plot of fold change versus false discovery rate (FDR) q values shows that 
upregulated TEs (red dots) form a substantial fraction of all TDP-43 dependent genes, and 
all are upregulated.
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(G) Knock down efficiency of short hairpin RNAs (shRNAs) targeting TARDBP was 
validated by western blot analysis and qPCR. For RNA levels, replicates were averaged and 
SD shown as error bars. For protein levels, western blots of the two biological replicates are 
shown separately.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-GAPDH antibody Cell Signaling Technology Cat# 5174, RRID:AB_10622025
Anti-IBA1 antibody EnCor Biotechnology Cat# RPCA-IBA1, RRID:AB_2722747
Anti-phospho-TARDBP antibody (pS409/410) Cosmo Bio Co., Ltd Cat# TIP-PTD-M01, RRID:AB_1961900
Anti-TARDBP antibody Proteintech Group Cat# 10782-2-AP, RRID:AB_615042
Anti-alpha-tubulin antibody CSHL monoclonal antibody 
collection
Clone DM1A, RRID:AB_5216186
HRP-linked anti-mouse IgG Cell Signaling Technology Cat# 7076, RRID:AB_330924
HRP-linked anti-rabbit IgG Cell Signaling Technology Cat# 7074, RRID:AB_2099233
Biological Samples
Postmortem frontal and motor cortex samples from ALS 
patients and unaffected individuals
NYGC ALS Consortium N/A
Postmortem motor cortex samples from ALS patients and 
unaffected individuals
UCSD N/A
Critical Commercial Assays
AmplideX PCR/CE C9ORF72 Kit Asuragen Cat# 49581
Bolt 4-12% Bis-Tris Plus Gel ThermoFisher Scientific Cat# NW04120BOX
PowerUp SYBR Green Master Mix ThermoFisher Scientific Cat# A25741
SuperSignal West Pico PLUS Chemiluminescent Substrate ThermoFisher Scientific Cat# 34577
Deposited Data
NYGC ALS Consortium RNA-seq datasets GEO GEO: GSE124439
UCSD ALS RNA-seq datasets GEO GEO: GSE122650
TARDBP knockdown in SH-SY5Y cell line GEO GEO: GSE122650
TARDBP eCLIP in SH-SY5Y cell line GEO GEO: GSE122650
Experimental Models: Cell Lines
SH-SY5Y cell line ATCC Cat# CRL-2266, RRID:CVCL_0019
HEK293FT cell line ThermoFisher Scientific Cat# R70007, RRID:CVCL_6911
Oligonucleotides
See Table S4 N/A
Recombinant DNA
MISSION® pLKO.1-puro Human TDP-43/TARDBP 
shRNA plasmid
Genetic Perturbation Platform ID# TRCN0000016038
MISSION® pLKO.1-puro Luciferase shRNA Control 
Plasmid
Sigma Aldrich Cat# SHC007
MISSION® pLKO.1-puro Non-Target shRNA Control 
Plasmid DNA
Sigma Aldrich Cat# SHC016
psPAX2 Gift from Didier Trono RRID:Addgene_12260
pMD2.G Gift from Didier Trono RRID:Addgene_12259
Software and Algorithms
CLAM v1.1.3 Zhang and Xing, 2017 https://github.com/Xinglab/CLAM
DESeq2 V1.22.2 Love et al., 2014 RRID:SCR_015687
GSEA v3.0 Subramanian et al., 2005 RRID:SCR_003199
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REAGENT or RESOURCE SOURCE IDENTIFIER
QuPath Bankhead et al., 2017 https://qupath.github.io/
SAKE v1.0 Ho et al., 2018 https://github.com/naikai/sake
STAR v2.5.2b Dobin et al., 2013 RRID:SCR_015899
TEtranscripts (TEToolkit) v2.0.3 Jin et al., 2015 https://github.com/mhammell-laboratory/
tetoolkit
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